Granted Patent
B2
US 7,947,290 · App. 12/644,952 · Granted May 24, 2011
Protease-resistant modified SEB and vaccine containing the same
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof.
Claims (1)
1. A modified Staphylococcal enterotoxin B (SEB) comprising the modified amino acid sequence of SEQ ID NO:1, wherein the lysines at positions 97 and 98 have been substituted with serines.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 22, 2013
From: KOWA COMPANY, LTC.
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 030068/0486 →
CHANGE OF NAME
Recorded Dec 14, 2012
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029474/0262 →
CONFIRMATORY LICENSE
Recorded Apr 22, 2010
From: UNIVERSITY OF PENNSYLVANIA (
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024269/0629 →
Priority Claims (1)
JP 2003-314187
· Sep 5, 2003
· national
Continuity (2)
Continuation
10570499